Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTH522 vaccine in healthy women
NCT02787109Phase 1Completed
- Sponsor
- Statens Serum Institut
- Start
- Jul 2016
- Primary completion
- Jul 2017
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CTH522 in Chlamydia trachomatis infection (3 arms), sponsored by Statens Serum Institut. Primary endpoint: Adverse Events. Started Jul 2016; status: completed.
02
Drugs
CTH522
03
Conditions
Chlamydia trachomatis infection
Beyond the preview
Go deeper on NCT02787109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02787109.